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1. Abstract
ELOVL family member 6, elongation of very long chain fatty 
acids (Elovl6), is a microsomal enzyme that regulates the 
elongation of C12-16 saturated and monounsaturated fatty 
acids (FAs) and has been shown to be related to the development 
of obesity-induced insulin resistance via modifying FA 
composition. In this study, we investigated the role of Elovl6 in 
pancreatic islet and -cell function. Elovl6 was expressed in islet 
and -cell line. Compared to wild-type (WT) mice, islets from 
Elovl6−/− mice displayed a normal architecture and -cell mass 
in a chow-fed state, but the islet hypertrophy by a high-fat, 
high-sucrose (HFHS) diet was attenuated. Glucose-stimulated 
insulin secretion (GSIS) was increased in the islet of the HFHS 
diet-fed Elovl6−/− mice than that of WT mice. Enhanced GSIS in 
the HFHS Elovl6−/− islets was associated with increased 
ATP/ADP ratio and suppression of ATF-3 expression. Our data 
suggest that Elovl6 could be involved in insulin secretory 
capacity and diabetes. 
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2. Introduction
Obesity is a major cause of type 2 diabetes (T2D) in 
humans because of the progressive deterioration of pancreatic 
-cell insulin secretory function and its capacity to compensate 
for increased peripheral insulin resistance [1] [2]. Accumulation 
of lipids in non-adipose tissues has been implicated in both 
pathologies, a phenomenon known as lipotoxicity as a molecular 
link between obesity and glucose homeostasis dysregulation [3] 
[4]. Pancreatic -cells are known to be highly susceptible to 
lipotoxicity, and both exogenous and endogenous sources of FAs 
are believed to be involved in the deterioration of -cell function. 
FA composition of the lipid species could be another 
determinant of the development of lipotoxicity. ELOVL family 
member 6, elongation of very long chain fatty acids (Elovl6) is a 
microsomal enzyme involved in the elongation of saturated and 
monounsaturated FAs with 12, 14, and 16 carbons [5] [6]. Loss 
of Elovl6 function reduces stearate (C18:0) and oleate (C18:1n-9) 
levels, and increases palmitate (C16:0) and palmitoleate 
(C16:1n-7) levels [7]. In our previous study, we have reported 
that mice with targeted disruption of Elovl6 (Elovl6−/−) are 
protected against hepatic insulin resistance development when 
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fed a HFHS diet despite hepatosteatosis and obesity in these 
mice and the wild-type mice being similar, suggesting that FA 
composition, particularly C16:0 to C18:0 conversion, is crucial 
for insulin sensitivity rather than mere lipid accumulation [7]. 
Therefore, inhibition of Elovl6 could be a potential therapeutic 
target for T2D. A major unanswered question is whether the 
inhibition of this elongase will leads to reduced susceptibility to 
pancreatic -cell failure. Here, we studied whether Elovl6 
participates in the regulation of insulin secretion and -cell 
function. 
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3. Materials and methods 
 
3.1 Animals.   
All animal husbandry and animal experiments were consistent 
with the University of Tsukuba’s Regulation of Animal 
Experiments and were approved by the Animal Experiment 
Committee of University of Tsukuba. Homozygous Elovl6−/− and 
sex- and age-matched Elovl6+/+ littermates housed in a 
pathogen-free barrier facility with 12 h light/12 h dark cycle, 
were maintained on a standard laboratory chow or HFHS diet 
[7]. 
 
3.2 Cell culture.   
Mouse insulinoma MIN6 cells and mouse hepatoma hepa1c1c7 
cells were cultured as described previously [8] [7]. 
 
3.3 Isolation of pancreatic islet.   
The isolation of mouse pancreatic islets was carried out 
according to the collagenase digestion methods described 
previously [9]. 
 
3.4 Analysis of insulin secretion, insulin content, and DNA 
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content of islets. 
Isolated islets were incubated for 2 h in RPMI-1640 medium 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 
mg/ml streptomycin. Ten islets were then preincubated for 30 
min in 2.8 mM glucose in 0.5% BSA Krebs-Ringer Bicarbonate 
Hepes (KRBH) buffer. Finally, they were incubated in 2.8 mM 
glucose, 20 mM glucose, or 2.8 mM glucose with 30 mM KCl in 
0.5% BSA KRBH buffer for 30 min, and insulin secretion was 
analyzed using mouse insulin ELISA kit (Shibayagi). Insulin 
secretion, insulin and DNA contents of the islets were measured 
as previously described [10]. 
3.5 Measurement of ATP and ADP content of islets. 
ATP and ADP levels per 10 isolated islets were measured as 
described previously, using the CellTiter-Glo Luminescent Cell 
Viability Assay (Promega) [10]. 
3.6 Measurement of triglycerides content of islets. 
One hundred isolated islets were used for lipid extraction. 
Triglycerides were measured by extracting lipids using the 
method of Folch [11], followed by triglyceride determination 
with the GPO-trinder kit (Sigma) [10]. 
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3.7 Fatty acid composition of islets.   
Total lipid was extracted from isolated islets (400 islets/sample) 
according to Bligh-Dyer’s procedure [12]. After saponification, 
the fatty acids in each sample were methyl-esterified and the 
relative abundance of each fatty acid was quantified by gas 
chromatography as described previously [7]. 
 
3.8 Gene expression.   
Total RNA extraction with the NucleoSpin RNA (TaKaRa) was 
performed according to the manufacture’s instruction. cDNA 
was synthesized with the PrimeScript RT Master kit (TaKaRa) 
and real-time PCR analysis was performed using SYBR Green 
Dye (GeneAce SYBR qPCR Mix , NIPPON GENE) with an ABI 
7300 instrument (Applied Biosystems) as previously described 
[10]. mRNA levels were normalized to cyclophilin expression. 
 
3.9 Histology and quantification of islet mass.   
Mice were euthanized, and the pancreases were excised, fixed in 
10% neutral buffered formalin, embedded in paraffin, and 
stained with hematoxylin & eosin. 
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3.10 Statistics. 
Data were represented as means ± SEM. Unpaired Student’s 
t-test was used for measuring the statistical significance of 
differences between two groups. P < 0.05 was considered of 
statistical significance. 
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4. Results 
 
4.1 Elovl6 is expressed in pancreatic islet and -cell lines 
Real-time PCR analysis revealed that Elovl6 mRNA was 
detected in isolated mouse islets as well as MIN6 cells (Figure 
1A and B). Elovl6 expression in isolated islets is comparable to 
that in brain, liver, and white adipose tissue, where Elovl6 plays 
a regulatory role. 
 
4.2 Morphology of islets of Elovl6−/− mice 
Chronic hyperinsulinemia due to insulin resistance is 
associated with hyperplasia and hypertrophy of islets caused by 
the adaptive proliferation of -cells to maintain blood glucose 
level. To determine whether endogenous Elovl6 is involved in 
the regulation of -cell function under conditions of obesity, WT 
and Elovl6−/− mice were fed a chow or HFHS diet for 12 weeks. 
Histology of pancreatic sections demonstrated that Elovl6−/− 
mice display no apparent morphological abnormalities of the 
islet on chow-fed state (Figure 2A). WT mice fed a HFHS diet 
showed a marked increase in size of islets, suggesting an 
adaptive enlargement of -cell mass in response to insulin 
resistance (Figure 2A). In contrast, islet hypertrophy was 
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suppressed in the HFHS Elovl6−/− pancreas compared to WT 
mice (Figure 2A and B), presumably at least in part because 
Elovl6 deletion ameliorates the development of diet-induced 
insulin resistance [7]. Staining with antibodies against insulin 
and glucagon evidenced that the organization of - and -cells 
was preserved in Elovl6−/− islet (Figure 2C). 
4.3 GSIS is improved in islets isolated from Elovl6/ mice 
Insulin secretion was estimated from islets isolated from 
WT and Elovl6−/− mice fed a chow or HFHS diet for 12 weeks 
(Figure 3A). Basal insulin secretion in low-glucose medium (2.8 
mM) was similar between WT and Elovl6−/− mice in both 
nutritional states. Insulin secretion in high glucose medium (20 
mM) was slightly decreased in the HFHS WT islets compared 
with the chow WT islets. Conversely, the HFHS Elovl6−/− islets 
exhibited significantly higher insulin secretion than the chow 
Elovl6/ islets and HFHS WT islets. Insulin secretion 
stimulated by KCl was slightly, but significantly increased in 
the chow Elovl6−/− islets than that of WT islets. 
Islet contents of insulin (Figure 3B) and triglycerides 
(TG) (Fig. 3c) of Elovl6−/− islets were indistinguishable from 
those of WT islets in the chow-fed state, and these contents in 
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islets were increased similar both WT and Elovl6−/− islets by 
HFHS diet. Consistent with enhanced GSIS, the ATP/ADP ratio 
of the HFHS Elovl6−/− islets was significantly increased than 
that of the HFHS chow islets (Figure 3D). 
4.4 Elovl6 deficiency alters islet FA composition 
To estimate the impact of Elovl6 deficiency on FA 
composition in pancreatic islets, we analyzed FA composition of 
islets isolated from WT and Elovl6−/− mice fed the chow or HFHS 
diet for 12 weeks (Figure 4A). There were no significant 
differences in C16:0, C16:1, C18:0 or C18:1 FA composition 
between WT and Elovl6−/− mice on a chow diet. Islet FA 
composition of the HFHS Elovl6/ mice showed decreased C18:0 
and increased C18:1 compared with the HFHS WT mice. The 
ratio of C18:0/C16:0, the marker of the Elov6 activity, was 
consistently decreased in the islets of Elovl6−/− mice as compared 
to WT controls in both nutritional states. The ratio of 
C18:1/C18:0, the marker of the SCD activity, was increased the 
islets of the HFHS Elovl6−/− mice as compared to WT mice. 
4.5 SREBP-1c and ATF-3 are downregulated in Elovl6−/− islets. 
Expression of various genes in islets was estimated by 
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real-time PCR to elucidate the molecular mechanism for 
enhanced insulin secretion of the HFHS Elovl6−/− islets. 
Expression of lipogenic genes, including Elovl6 and sterol 
regulatory element binding protein (SREBP) -1c were not 
different but that of fatty acid synthase (FAS) and stearoyl-CoA 
desaturase (SCD)-1 were decreased in the HFHS WT mice 
compared with the chow WT mice (Figure 4B). Expression of 
SREBP-1c and its target genes FAS and SCD-1 were repressed 
in the islets of chow Elovl6−/− mice versus chow WT mice. 
Expression of SREBP-1c was decreased, but FAS and SCD-1 
were increased in the islets of the HFHS Elovl6−/− mice versus 
the HFHS WT mice. Gene expression of uncoupling protein 
(UCP)-2, a SREBP target established to disrupt -cell energy 
metabolism and insulin secretion [13] [14], was significantly 
increased in the islets of HFHS-fed WT mice, but not in the 
Elovl6−/− islets, explaining increased ATP/ADP ratio in the 
HFHS Elovl6−/− islets (Figure 4B). Expression of Pancreatic and 
duodenal homeobox factor-1 (PDX-1) and musculoaponeurotic 
fibrosarcoma oncogene family A (MafA), two master 
transcription factors regulating the insulin gene and GSIS in 
the mature -cell[15], were decreased in islets of the chow 
Elovl6−/− mice versus chow WT mice, but coordinately repressed 
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by HFHS diet in both group of mice (Figure 4C). The expression 
levels of insulin receptor substrate (IRS)-2 and glucose 
transporter (GLUT)-2 were similar between WT and Elovl6/ 
mice (Figure 4C). In WT mice, expression of activating 
transcription factor (ATF)-3, the integrated stress response gene 
involved in -cell dysfunction and apoptosis [16,17,18,19,20], 
was induced significantly by the HFHS diet (Figure 4D). 
Strikingly, Elovl6−/− mice displayed markedly lower expression 
of ATF-3 by the HFHS diet. 
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Discussion 
In the present study, we show that Elovl6 mRNA is 
expressed in mouse islets and -cell line MIN6 cells. Real 
time-PCR analysis revealed that C57BL/6J mice significantly 
express Elovl6 in the islets. Elovl6 expression in isolated islets 
is comparable to that in brain, liver, and white adipose tissue 
(WAT) where Elovl6 plays a regulatory role [6] [7] [21]. The 
chow-fed Elovl6−/− mice do not display on altered islet 
morphology and -/-cell distribution, suggesting that Elovl6 is 
not required for the maintenance of islet architecture or -cell 
mass in mice under normal conditions. However, analysis of the 
expression of several genes related to FA metabolism and islet 
function revealed decreased levels in the chow Elovl6−/− islets. 
SREBP-1c, FAS, and SCD-1 contribute to FA synthesis [22], and 
PDX-1 and MafA contribute to -cell specific and 
glucose-responsive insulin gene transcription, suggesting that 
Elovl6 plays some roles in the islet function. 
Our findings indicate that Elovl6−/− mice resist HFHS 
diet-induced islet hypertrophy at least in part as a result of 
enhanced insulin secretion. As shown previously, Elovl6−/− mice 
were protected from the HFHS diet-induced hepatic insulin 
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resistance[7]. In addition, IRS-2, reported to be important for 
growth and survival of -cells, was sustained in islets of 
Elovl6−/− mice. Thus, the attenuated -cell expansion in the 
HFHS Elovl6−/− mice could be due to the combined effects of the 
ameliorated insulin resistance and enhanced GSIS per -cell. 
Our results also indicated that the enhanced GSIS in the 
HFHS Elovl6−/− islets is not due to increased insulin contents or 
reduced islet triglyceride contents but mediated through the 
elevation of ATP/ADP ratio at high glucose concentration. 
UCP-2, which has the proton leak activity and negative effects 
on ATP synthesis, was markedly upregulated in the HFHS WT 
islets, whereas it was increased only slightly in the HFHS 
Elovl6−/− islets, indicating that the improved glucose metabolism 
in -cells partially contributed to the increment of GSIS. 
One important aspect of this study is the potential effect 
of cellular FA composition on -cell function. Our results show 
that the ratio of stearate in pancreatic islet is higher than that 
of other tissues such as liver, adipose tissue, and muscle. The 
relative amounts of C18:0 and the ratio of C18:0/C16:0 were 
significantly reduced by Elovl6 deficiency after the HFHS diet. 
Furthermore, the increase in the ratio of C18:1 to C18:0, which 
is consistent with the increased expression of SCD1 in the islets 
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of HFHS Elovl6−/− mice, could rescues saturated FAs-induced 
islets dysfunction. Recently, Green et al. clearly demonstrated 
that knockdown of Elovl6 or overexpression of SCD2 in INS1 
-cells attenuated palmitate-induced ER stress and apoptosis 
[23]. These results suggest that the fatty acid composition of 
Elovl6−/− islets, namely the reduction of C18 FAs and the high 
ratio of C18:1/C18:0, may be protective against islet lipotoxicity 
in HFHS-fed mice. 
Suppression of ATF-3 expression in islets of the HFHS 
Elovl6−/− mice could play an important role in molecular 
mechanism for enhanced GSIS. It has been demonstrated that 
ATF-3 is induced by signals relevant to the pancreatic -cell 
dysfunction such as proinflammatory cytokines, ROS, ER stress, 
and high concentration of glucose and FAs [16]. In addition, 
ATF-3 is involved in the reduction of PDX-1, which leads to 
pancreatic -cell dysfunction and apoptosis [18]. Considering 
that, suppression of this factor could explain the improved -cell 
function that was observed in the HFHS Elovl6−/− mice, 
although the molecular link between Elovl6 and ATF-3 remains 
to be elucidated. 
The phenotypes observed in Elovl6−/− mice leave 
unanswered the question of the role of Elovl6 in -cell. In our 
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study, it was not possible to distinguish in which islet cell type 
Elovl6 mRNA is expressed. Since deficiency of Elovl6 raises 
numerable changes caused from phenotype of liver or the other 
tissues [7] [24] [25] [26], pancreatic -cell-specific deletion will 
be required to further determine the precise role of Elovl6 on 
pancreatic -cells. 
In conclusion, our results show that Elovl6 is expressed in 
pancreatic islet and -cell and that Elovl6 deficiency inhibits 
impaired GSIS in obese mice. These findings suggest that this 
FA elongase may be involved in the regulation of islet function 
and open promising new perspectives for the prevention of T2D. 
Further studies are needed to clarify the details and the precise 
mechanisms of a link between FAs and insulin secretion. 
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Figure Legends 
Fig. 1.  Elovl6 is expressed in pancreatic islets and -cells. (A) 
Elovl6 mRNA levels in the pancreatic islets and various tissues 
of 14-16 week-old male C57BL/6J mice (n = 3). (B) Elovl6 mRNA 
levels in Hepa1c1c7 hepatoma cells and MIN6 cells (n = 4-5). 
Fig. 2.  Islet morphology of Elovl6−/− mice. (A) Representative 
pancreatic sections of wild-type (WT) and Elovl6−/− mice fed a 
chow or HFHS diet for 12 weeks stained with hematoxylin and 
eosin for histological analysis. (B) Islet mass under HFHS diet 
were quantified using NIH image. At least 30 islets from each 
pancreas were quantified and total number of islets scanned 
was 275-291 for each genotype (n = 7).  P < 0.01. (C) 
Representative pancreatic sections of WT and Elovl6−/− mice fed 
a HFHS diet stained with insulin (red) and glucagon (green). 
Scale bar, 50μm.
Fig. 3. Elovl6 deficiency results in enhanced islet 
glucose-stimulated insulin secretion and increased ATP/ADP 
ratio. (A) Glucose- or KCl- stimulated insulin secretion from 
24 
isolated islets of WT and Elovl6−/− mice fed a chow or HFHS diet 
for 12 weeks (n = 6). (B-D) Insulin contents (n = 4) (B), 
triglyceride contents (n = 4) (C), and ATP/ADP ratio (n = 5-6) (D) 
in isolated islets of WT and Elovl6−/− mice fed a chow or HFHS 
diet for 12 weeks.  P < 0.05,  P < 0.01. 
Fig. 4.  FA composition and gene expression profile in isolated 
islets from WT and Elovl6−/− mice fed a chow or HFHS diet. (A) 
Islet FA composition of WT and Elovl6−/− mice fed a chow or 
HFHS diet for 12 weeks (n = 3-4).  P < 0.05,  P < 0.01. (B-D) 
mRNA levels of genes involved in FA metabolism (B), important 
for -cell function (C), and ATF3 (D) in isolated islets from WT 
and Elovl6−/− mice fed a chow or HFHS diet for 12 weeks (n = 
4-8).  P < 0.05,  P < 0.01. 
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